Table 1.
Baseline demographics and patient‐reported outcomesa
| Demographics and PROs | SC abatacept + MTX (n = 318) | Adalimumab + MTX (n = 328) |
|---|---|---|
| Age, years | 51.4 ± 12.6 | 51.0 ± 12.8 |
| Women, % | 81.4 | 82.3 |
| White, % | 80.8 | 78.0 |
| Disease duration, years | 1.9 ± 1.4 | 1.8 ± 1.4 |
| HAQ DI score | 1.5 ± 0.7 | 1.5 ± 0.7 |
| DAS28‐CRP score | 5.5 ± 1.1 | 5.5 ± 1.1 |
| Pain scoreb | 63.1 ± 22.3 | 65.5 ± 21.8 |
| Fatigue scoreb | 60.6 ± 25.0 | 60.1 ± 25.4 |
| Ability to perform work scorec | ||
| Percentage work time missed | 10.9 ± 21.5 | 13.5 ± 25.1 |
| Percentage impairment at work | 47.2 ± 28.5 | 51.4 ± 27.7 |
| Percentage overall work impairment | 50.2 ± 29.5 | 54.4 ± 29.6 |
| Percentage activity impairment | 56.3 ± 24.6 | 57.1 ± 25.9 |
| Ability to perform daily activities score, daysd | 11.7 ± 10.4 | 12.4 ± 10.3 |
Values are mean ± SD unless indicated otherwise. Baseline fatigue, ability to perform work, and ability to perform daily activities scores presented for patients with available data at 2 years (abatacept and adalimumab, respectively: fatigue, n = 310 and n = 315; work time missed, n = 137 and n = 130; impairment at work, overall work impairment, and activity impairment, n = 134 and n = 126; ability to perform daily activities, n = 308 and n = 310). SC = subcutaneous; MTX = methotrexate; HAQ DI = Health Assessment Questionnaire disability index; DAS28‐CRP = Disease Activity Score in 28 joints using the C‐reactive protein level.
Pain and fatigue measured on a visual analog scale with 100‐mm score.
Ability to perform work assessed using the Work Productivity and Activity Impairment Questionnaire: Rheumatoid Arthritis.
Ability to perform daily activities assessed as the number of days that patients were unable to perform normal activities during the past 30 days using the Activity Limitation Questionnaire.